Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Patent
1997-06-11
2000-12-05
Guzo, David
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
424 936, 435 691, 4353201, 435455, 435456, 435457, 435462, 435463, 435325, 435366, 435371, 536 2372, 536 243, A61K 4800, C12N 15864, C12N 1564, C12N 510
Patent
active
06156303&
ABSTRACT:
The present invention provides isolated adenovirus-associated viruses ("AAV"), including AAV isolates designated AAV3B and AAV6. The invention also provides nucleic acid molecules of AAV3B (SEQ ID NO: 1) or AAV6 (SEQ ID NO: 2), including DNA or RNA, and provides substantially purified polypeptides encoded by AAV3B or AAV6, as well as antibodies specific for such polypeptides. The invention also provides infectious AAV3B and AAV6 clones; AAV viral vectors, which can be hybrid AAV viral vectors; AAV vector plasmids; and AAV helper plasmids; each comprising at least a portion of an AAV3B (SEQ ID NO: 1) or AAV6 (SEQ ID NO: 2) nucleic acid molecule. The invention further provides host cells containing at least a portion of an AAV3B or AAV6 nucleic acid molecule and progeny cells derived therefrom, and provides non-human transgenic mammals having an AAV vector genome stably integrated in a chromosome. The invention also provides methods of producing a polypeptide or an RNA by expressing the polypeptide or the RNA from an AAV viral vector in a cell, and methods of treating a pathologic condition in a mammal, comprising transducing cells of the mammal with an AAV viral vector containing a heterologous nucleic acid sequence. The invention also provides AAV3B or AAV6 nucleotide sequences, which can be useful, for example, as probes for identifying the presence of AAV3B or AAV6 nucleic acids in a sample. The present invention further provides a method of identifying an AAV viral vector suitable for administration to an individual.
REFERENCES:
patent: 5252479 (1993-10-01), Srivastava
patent: 5587308 (1996-12-01), Carter
patent: 5858351 (1999-01-01), Podsakoff et al.
Muramatsu et al., "Nucleotide Sequencing and Generation of an Infectious Clone of Adeno-Associated Virus 3," Virology 221:208-217 (1996).
Srivastava et al., "Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome," J. Virol. 45:555-564 (1983).
Alexander et al., "Effects of Gamma Irradiation on the Transduction of Dividing and Nondividing Cells in Brain and Muscle of Rats by Adeno-Associated Virus Vectors," Human Gene Ther. 7:841-850 (1996).
Flotte et al., "Stable in vivo Expression of the Cystic Fibrosis Transmembrane Conductance Regulator with an Adeno-Associated Virus Vector," Proc. Natl. Acad. Sci., USA 90:10613-10617 (1993).
Russell et al., "Adeno-Associated Virus Vectors Preferentially Transduce Cells in S Phase," Proc. Natl. Acad. Sci., USA 91:8915-8919 (1994).
Halbert et al., "Adeno-Associated Virus Vectors Transduce Primary Cells Much Less Efficiently than Immortalized Cells," J. Virol. 69:1473-1479 (1995).
Mizukami et al., "Adeno-Associated Virus Type 2 Binds to a 150-Kilodalton Cell Membrane Glycoprotein," Virology 217:124-130 (1996).
Clark et al., "Cell Lines for the Production of Recombinant Adeno-Associated Virus," Hum. Gene Ther. 6:1329-1341 (1995).
Russell David W.
Rutledge Elizabeth A.
Guzo David
University of Washington
LandOfFree
Adeno-associated virus (AAV) isolates and AAV vectors derived th does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adeno-associated virus (AAV) isolates and AAV vectors derived th, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adeno-associated virus (AAV) isolates and AAV vectors derived th will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-958870